ATE551325T1 - Therapeutische morpholino-substituierte verbindungen - Google Patents
Therapeutische morpholino-substituierte verbindungenInfo
- Publication number
- ATE551325T1 ATE551325T1 AT07009194T AT07009194T ATE551325T1 AT E551325 T1 ATE551325 T1 AT E551325T1 AT 07009194 T AT07009194 T AT 07009194T AT 07009194 T AT07009194 T AT 07009194T AT E551325 T1 ATE551325 T1 AT E551325T1
- Authority
- AT
- Austria
- Prior art keywords
- kinase
- diseases
- compounds
- morpholino
- conditions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 3
- 150000003906 phosphoinositides Chemical class 0.000 abstract 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000007536 Thrombosis Diseases 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 206010002388 Angina unstable Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010011086 Coronary artery occlusion Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 208000032612 Glial tumor Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- -1 Morpholino-substituted pyridopyrimidine Chemical class 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000007814 Unstable Angina Diseases 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical class C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 208000000587 small cell lung carcinoma Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/64—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with oxygen atoms directly attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Pyrane Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17735100P | 2000-01-24 | 2000-01-24 | |
| US22582600P | 2000-08-17 | 2000-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE551325T1 true ATE551325T1 (de) | 2012-04-15 |
Family
ID=26873182
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01902568T ATE363471T1 (de) | 2000-01-24 | 2001-01-24 | Durch einen morpholinrest substituierte therapeutische verbindungen |
| AT07009194T ATE551325T1 (de) | 2000-01-24 | 2001-01-24 | Therapeutische morpholino-substituierte verbindungen |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01902568T ATE363471T1 (de) | 2000-01-24 | 2001-01-24 | Durch einen morpholinrest substituierte therapeutische verbindungen |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US6977255B2 (enExample) |
| EP (2) | EP1257537B1 (enExample) |
| JP (1) | JP4820518B2 (enExample) |
| CN (3) | CN1263743C (enExample) |
| AT (2) | ATE363471T1 (enExample) |
| AU (2) | AU3042601A (enExample) |
| CA (1) | CA2398163C (enExample) |
| CY (1) | CY1108023T1 (enExample) |
| DE (1) | DE60128655T2 (enExample) |
| DK (1) | DK1257537T3 (enExample) |
| ES (1) | ES2286093T3 (enExample) |
| NZ (1) | NZ520300A (enExample) |
| PT (1) | PT1257537E (enExample) |
| WO (1) | WO2001053266A1 (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100785363B1 (ko) | 2000-04-25 | 2007-12-18 | 이코스 코포레이션 | 인간 포스파티딜-이노시톨 3-키나제 델타의 억제제 |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| GB0119863D0 (en) | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| GB0119865D0 (en) * | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| GB2405093B (en) * | 2001-08-14 | 2005-07-06 | Cancer Rec Tech Ltd | DNA-PK inhibitors |
| TW589181B (en) * | 2001-09-05 | 2004-06-01 | Eisai Co Ltd | Lymphocytic activation inhibitor and remedial agent for autoimmune disease |
| US7049313B2 (en) | 2002-02-25 | 2006-05-23 | Kudos Pharmaceuticals Ltd. | ATM inhibitors |
| EP2311818B1 (en) * | 2002-02-28 | 2013-01-16 | Novartis AG | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug |
| TWI314928B (en) | 2002-02-28 | 2009-09-21 | Novartis A | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
| NZ538420A (en) * | 2002-08-16 | 2007-06-29 | Kinacia Pty Ltd | Inhibition of phosphoinositide 3-kinase beta |
| CN101260104A (zh) * | 2002-08-16 | 2008-09-10 | 阿斯利康(瑞典)有限公司 | 抑制磷酸肌醇3-激酶β |
| AU2003265585B2 (en) | 2002-08-26 | 2008-07-03 | Takeda Pharmaceutical Company Limited | Calcium receptor modulating compound and use thereof |
| AU2003280188A1 (en) | 2002-12-06 | 2004-06-30 | Warner-Lambert Company Llc | Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k |
| GB0305152D0 (en) * | 2003-03-06 | 2003-04-09 | Novartis Ag | Organic compounds |
| JP2006522124A (ja) * | 2003-04-03 | 2006-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用な組成物 |
| JP2006523237A (ja) * | 2003-04-03 | 2006-10-12 | セマフォア ファーマシューティカルズ， インコーポレイテッド | Ｐｉ−３キナーゼインヒビタープロドラッグ |
| EP1636212B1 (en) * | 2003-06-05 | 2007-06-27 | Warner-Lambert Company LLC | Cycloalkylsulfanyl substituted benzo¬b|thiophenes as therapeutic agents |
| CA2527934A1 (en) * | 2003-06-05 | 2004-12-16 | Warner-Lambert Company Llc | Tetrazol benzofurancarboxamides with p13k activity as therapeutic agents |
| US20040259926A1 (en) * | 2003-06-05 | 2004-12-23 | Bruendl Michelle M. | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents |
| AU2004265149A1 (en) | 2003-08-13 | 2005-02-24 | Kudos Pharmaceuticals Limited | Aminopyrones and their use as ATM inhibitors |
| MXPA06002513A (es) * | 2003-09-04 | 2006-06-20 | Warner Lambert Co | Benzo[b]tiofenos halo-sustituidos con actividad inhibidora de fosfoinositido-3-cinasas (pi3k) como agentes terapeuticos. |
| WO2005042519A1 (en) * | 2003-10-31 | 2005-05-12 | Warner-Lambert Company Llc | Pyrimidines as inhibitors of phosphoinositide -3-kinases (pi3k) |
| JP2007519742A (ja) * | 2004-01-26 | 2007-07-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼの阻害剤として有用な組成物 |
| ES2873875T3 (es) | 2004-05-13 | 2021-11-04 | Icos Corp | Quinazolinonas como inhibidores de fosfatidilinositol 3-quinasa delta humano |
| CN1300163C (zh) * | 2004-06-23 | 2007-02-14 | 南京大学 | 3－羟基色原酮糖苷及其制法和用途 |
| JP2008513428A (ja) | 2004-09-20 | 2008-05-01 | クドス ファーマシューティカルズ リミテッド | Ｄｎａ−ｐｋ阻害剤 |
| US7642254B2 (en) | 2005-02-09 | 2010-01-05 | Kudos Pharmaceuticals Limited | ATM inhibitors |
| AR053358A1 (es) * | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
| WO2007127366A2 (en) | 2006-04-25 | 2007-11-08 | Targegen, Inc. | Kinase inhibitors and methods of use thereof |
| DK2044026T3 (da) * | 2006-06-22 | 2014-06-30 | Prana Biotechnology Ltd | Fremgangsmde til behandling af cerebral glioma tumor |
| WO2008102932A1 (en) * | 2007-02-21 | 2008-08-28 | Biobud Co., Ltd. | Compositions for treating hyperproliferative vascular disorders and cancers |
| EP2157092A4 (en) | 2007-04-11 | 2011-04-13 | Ajinomoto Kk | Remedy for diabetes |
| JP2010529031A (ja) * | 2007-05-29 | 2010-08-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体 |
| WO2009008991A2 (en) * | 2007-07-06 | 2009-01-15 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Dna-pkcs modulates energy regulation and brain function |
| JP2011510071A (ja) * | 2008-01-25 | 2011-03-31 | アストラゼネカ アクチボラグ | 鏡像異性的に純粋な（−）２−［１−（７−メチル−２−（モルホリン−４−イル）−４−オキソ−４Ｈ−ピリド［１，２−ａ］ピリミジン−９−イル）エチルアミノ］安息香酸、医学的療法における該物質の使用、および該物質を含む薬学的組成物−０２６ |
| JP2011518174A (ja) * | 2008-04-18 | 2011-06-23 | シェノゲン ファーマ グループ リミテッド | エストロゲン受容体に関連する疾患を処置するための化合物及び方法 |
| KR20110065536A (ko) | 2008-09-29 | 2011-06-15 | 서트리스 파마슈티컬즈, 인코포레이티드 | 시르투인 조절제로서의 퀴나졸리논, 퀴놀론 및 관련 유사체 |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| CA2743642C (en) | 2008-11-13 | 2017-09-19 | Calistoga Pharmaceuticals, Inc. | Therapies for hematologic malignancies |
| US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
| LT2448939T (lt) | 2009-07-02 | 2017-06-12 | Sanofi | 2,3-dihidro-1h-imidazo {1,2-a} pirimidin-5-ono dariniai, jų gamyba ir farmacinis panaudojimas |
| AR077628A1 (es) | 2009-07-02 | 2011-09-14 | Sanofi Aventis | Derivados de 6-(morfolin-4-il)-pirimidin-4(3h)-ona, su preparacion y su utilizacion farmaceutica como inhibidores de la fosforilacion de akt(pkb) |
| SI2448940T1 (sl) | 2009-07-02 | 2014-10-30 | Sanofi | Derivati 6,7,8,9-tetrahidro-pirimido(1,2-a)pirimidin-4-ona, njihova priprava in njihova farmacevtska uporaba |
| HRP20140478T1 (hr) | 2009-07-02 | 2014-07-04 | Sanofi | Novi derivati (6-okso-1,6-dihidropirimidin-2-il)amida, njihovo dobivanje, te farmaceutska upotreba kao inhibitora fosforilacije akt |
| MX2012000817A (es) | 2009-07-21 | 2012-05-08 | Gilead Calistoga Llc | Tratamiento para desordenes del higado con inhibidores pi3k. |
| US8399460B2 (en) | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
| IT1403156B1 (it) * | 2010-12-01 | 2013-10-04 | Università Degli Studi Di Torino | Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi. |
| WO2012085244A1 (fr) | 2010-12-23 | 2012-06-28 | Sanofi | Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique |
| FR2969612B1 (fr) * | 2010-12-23 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique |
| FR2969613B1 (fr) * | 2010-12-23 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique |
| PL2658844T3 (pl) | 2010-12-28 | 2017-04-28 | Sanofi | Nowe pochodne pirymidyn, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT(pkb) |
| TW201335151A (zh) * | 2012-01-26 | 2013-09-01 | Daiichi Sankyo Co Ltd | 具有骨形成促進作用之色酮衍生物 |
| PL2812004T3 (pl) * | 2012-02-10 | 2019-01-31 | Ptc Therapeutics, Inc. | Związki do leczenia rdzeniowego zaniku mięśni |
| EA029155B1 (ru) | 2012-03-01 | 2018-02-28 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения спинальной мышечной атрофии |
| MD20140100A2 (ro) | 2012-03-05 | 2015-01-31 | Gilead Calistoga Llc | Forme polimorfe ale (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilchinazolin-4(3H)-onei |
| MX358514B (es) | 2012-03-23 | 2018-08-24 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
| ITMI20120514A1 (it) * | 2012-03-29 | 2013-09-30 | Cnr Consiglio Naz Delle Ric Erche | Agente terapeutico per il trattamento dei vasi sanguigni |
| FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| US10195202B2 (en) | 2013-12-19 | 2019-02-05 | Ptc Therapeutics, Inc. | Methods for modulating the amount of RNA transcripts |
| US9708327B2 (en) | 2013-12-20 | 2017-07-18 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
| EP3594215A1 (en) | 2013-12-20 | 2020-01-15 | Gilead Calistoga LLC | Intermediate products in process methods for the preparation of phosphatidylinositol 3-kinase inhibitors |
| NZ726360A (en) | 2014-06-13 | 2018-04-27 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
| CN107635999B (zh) * | 2015-05-20 | 2020-09-25 | 豪夫迈·罗氏有限公司 | 用于治疗脊髓性肌萎缩的化合物 |
| US10668171B2 (en) | 2015-05-30 | 2020-06-02 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
| KR102488323B1 (ko) | 2015-12-10 | 2023-01-12 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 또는 개선을 위한 조성물 |
| WO2017103931A1 (en) | 2015-12-17 | 2017-06-22 | Biokine Therapeutics Ltd. | Small molecules against cancer |
| JP6941611B2 (ja) | 2015-12-17 | 2021-09-29 | バイオカイン セラピューティックス リミテッド | ケモカイン活性および／または癌細胞成長を阻害するための小分子 |
| EP3496724B8 (en) * | 2016-08-12 | 2021-11-17 | Madera Therapeutics, LLC | Protein kinase regulators |
| JP2019535789A (ja) | 2016-11-28 | 2019-12-12 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｒｎａスプライシングを調節する方法 |
| US11760762B2 (en) | 2017-01-27 | 2023-09-19 | Signalrx Pharmaceuticals, Inc. | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors |
| KR20200033249A (ko) | 2017-06-05 | 2020-03-27 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
| JP2020523365A (ja) | 2017-06-14 | 2020-08-06 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｒｎａスプライシングを改変する方法 |
| MX2019015578A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| US12103926B2 (en) | 2018-03-27 | 2024-10-01 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| AU2019294478B2 (en) | 2018-06-27 | 2023-03-23 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| CN109748914B (zh) * | 2018-12-29 | 2021-05-25 | 上海珂臻医药科技有限公司 | 吡啶并嘧啶类化合物及其应用 |
| CN114096524B (zh) | 2019-05-15 | 2025-03-04 | 阿龙拜欧有限公司 | 用于治疗癌症、抑制趋化因子活性和/或诱导细胞死亡的小分子 |
| AR121719A1 (es) | 2020-04-03 | 2022-06-29 | Petra Pharma Corp | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades |
| CN111533721B (zh) * | 2020-05-15 | 2022-04-26 | 浙江大学 | 苯并吡喃酮或喹啉酮类化合物及其应用 |
| US20240208964A1 (en) * | 2020-06-03 | 2024-06-27 | Pyridopyrimidines And Methods Of Their Use | Pyridopyrimidines and methods of their use |
| JP2024508045A (ja) * | 2021-02-01 | 2024-02-21 | ゲオデ セラピューティクス インコーポレイテッド | ホスホイノシチド３キナーゼベータ阻害剤ならびにそれらの組成物および方法 |
| AU2022268900B2 (en) | 2021-05-03 | 2024-12-19 | Petra Pharma Corporation | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
| KR20240014065A (ko) | 2021-05-27 | 2024-01-31 | 페트라 파마 코포레이션 | 암의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제 |
| TW202329930A (zh) | 2021-09-30 | 2023-08-01 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑 |
| EP4412606A4 (en) * | 2021-10-07 | 2025-09-24 | Relay Therapeutics Inc | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF |
| WO2025136936A1 (en) * | 2023-12-19 | 2025-06-26 | Merck Sharp & Dohme Llc | Agonists of trem2 activity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS604170A (ja) * | 1983-06-21 | 1985-01-10 | Nippon Shinyaku Co Ltd | キノロン誘導体 |
| US5703075A (en) * | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| JPH04502322A (ja) | 1988-12-21 | 1992-04-23 | ジ・アップジョン・カンパニー | 抗アテローム性動脈硬化症性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類 |
| JPH05509302A (ja) | 1990-06-20 | 1993-12-22 | ジ・アップジョン・カンパニー | 抗アテローム性動脈硬化性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類 |
-
2001
- 2001-01-24 CN CNB018067522A patent/CN1263743C/zh not_active Expired - Fee Related
- 2001-01-24 AT AT01902568T patent/ATE363471T1/de active
- 2001-01-24 DK DK01902568T patent/DK1257537T3/da active
- 2001-01-24 AU AU3042601A patent/AU3042601A/xx active Pending
- 2001-01-24 CN CNA2006100847155A patent/CN1891699A/zh active Pending
- 2001-01-24 PT PT01902568T patent/PT1257537E/pt unknown
- 2001-01-24 EP EP01902568A patent/EP1257537B1/en not_active Expired - Lifetime
- 2001-01-24 EP EP07009194A patent/EP1857443B1/en not_active Expired - Lifetime
- 2001-01-24 WO PCT/IB2001/000079 patent/WO2001053266A1/en not_active Ceased
- 2001-01-24 CA CA2398163A patent/CA2398163C/en not_active Expired - Fee Related
- 2001-01-24 AU AU2001230426A patent/AU2001230426C1/en not_active Ceased
- 2001-01-24 US US10/181,485 patent/US6977255B2/en not_active Expired - Fee Related
- 2001-01-24 DE DE60128655T patent/DE60128655T2/de not_active Expired - Lifetime
- 2001-01-24 JP JP2001553268A patent/JP4820518B2/ja not_active Expired - Fee Related
- 2001-01-24 NZ NZ520300A patent/NZ520300A/en not_active IP Right Cessation
- 2001-01-24 ES ES01902568T patent/ES2286093T3/es not_active Expired - Lifetime
- 2001-01-24 AT AT07009194T patent/ATE551325T1/de active
- 2001-01-24 CN CNA200610084723XA patent/CN1891693A/zh active Pending
-
2004
- 2004-10-12 US US10/961,062 patent/US7405211B2/en not_active Expired - Fee Related
-
2007
- 2007-07-20 CY CY20071100971T patent/CY1108023T1/el unknown
-
2008
- 2008-01-24 US US12/019,061 patent/US7572791B2/en not_active Expired - Fee Related
- 2008-05-06 US US12/115,563 patent/US20080312233A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE551325T1 (de) | Therapeutische morpholino-substituierte verbindungen | |
| WO2005082863A3 (en) | 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors | |
| JP2002525323A (ja) | 医薬活性化合物及びその使用方法 | |
| KR20100118977A (ko) | 거울상이성질체적으로 순수한 (-) 2-[1-(7-메틸-2-(모르폴린-4-일)-4-옥소-4Ｈ-피리도[1,2-α]피리미딘-9-일)에틸아미노]벤조산, 의학 치료에서의 이의 용도 및 이를 포함하는 약학 조성물-026 | |
| PT1000033E (pt) | Derivados heterociclicos que inibem o factor xa | |
| BR0011295A (pt) | Aril e heteroaril pirazinonas policìclicas substituìdas úteis para inibição seletiva de cascata de coagulação | |
| NO20064295L (no) | Bruk av metylenamidderivater i kardiovaskulaere lidelser | |
| BR9914893A (pt) | Cromenona e derivados de cromanona como inibidores de integrina | |
| JP2016512243A5 (enExample) | ||
| US4954519A (en) | Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents | |
| DE69624829D1 (de) | Thienopyrimidinderivate als endothelin antagonisten | |
| JPH05500805A (ja) | 抗血栓症作用を有する組合せ調剤 | |
| Golino et al. | Aurintricarboxylic acid reduces platelet deposition in stenosed and endothelially injured rabbit carotid arteries more effectively than other antiplatelet interventions | |
| CA2534171A1 (en) | Bicyclic indoline sulfonamide derivatives | |
| ATE179979T1 (de) | Triazolopyrimidinderivate als angiotensin-ii rezeptor antagonisten | |
| WO2001077097A3 (en) | Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade | |
| TR200103853T2 (tr) | Spiro bağlı trisiklik bileşikler. | |
| ATE315932T1 (de) | Hemmer für das 20-hete-produzierende enzym | |
| CN113116885A (zh) | 一种茶多酚类化合物在制备抗血栓药物中的应用 | |
| Radziwon et al. | Tissue factor pathway inhibitor (TFPI) in patients with occlusive arterial diseases in consideration with risk factors and conservative treatment of the disease | |
| Singla et al. | Interplay between Hemostatic Pathways and Cancer Biology in Head and Neck Cancers | |
| CN105085346B (zh) | 含胺基的l-薄荷醇类p2y12受体拮抗剂及其用途 | |
| Al-Horani et al. | BIOCHEMICAL INVESTIGATION OF THE ANTICOAGULANT ACTIVITY OF SULFONATED POLYMERS | |
| CN104610257B (zh) | 一类含酰胺结构的FXa抑制剂、制备方法及其用途 | |
| ATE491696T1 (de) | Neue 2,4-diaminothiazol-5-onderivate |